105 related articles for article (PubMed ID: 12635453)
41. Beneficial effect of long-term combined treatment with voglibose and pioglitazone on pancreatic islet function of genetically diabetic GK rats.
Ishida H; Kato S; Nishimura M; Mizuno N; Fujimoto S; Mukai E; Kajikawa M; Yamada Y; Odaka H; Ikeda H; Seino Y
Horm Metab Res; 1998 Nov; 30(11):673-8. PubMed ID: 9918384
[TBL] [Abstract][Full Text] [Related]
42. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
Pfützner A; Schöndorf T; Tschöpe D; Lobmann R; Merke J; Müller J; Lehmann U; Fuchs W; Forst T
Diabetes Technol Ther; 2011 Jun; 13(6):637-43. PubMed ID: 21457065
[TBL] [Abstract][Full Text] [Related]
43. Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada.
Coyle D; Palmer AJ; Tam R
Pharmacoeconomics; 2002; 20 Suppl 1():31-42. PubMed ID: 12036382
[TBL] [Abstract][Full Text] [Related]
44. Comparison of glycemic and lipid response to pioglitazone treatment in Mexican-Americans and non-Hispanic Caucasians with type 2 diabetes.
King AB; Armstrong DU; Chinnapongse S
Diabetes Care; 2003 Jan; 26(1):245-6. PubMed ID: 12502690
[No Abstract] [Full Text] [Related]
45. The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review.
Chilcott J; Wight J; Lloyd Jones M; Tappenden P
Health Technol Assess; 2001; 5(19):1-61. PubMed ID: 11701097
[No Abstract] [Full Text] [Related]
46. [Use of glitazones in type 2 diabetes: a critical position].
Richter B
Dtsch Med Wochenschr; 2001 May; 126(20):606. PubMed ID: 11402929
[No Abstract] [Full Text] [Related]
47. Effects of troglitazone on insulin sensitivity.
Henry RR
Diabet Med; 1996 Sep; 13(9 Suppl 6):S148-50. PubMed ID: 8894499
[TBL] [Abstract][Full Text] [Related]
48. Angioneurotic edema as a side effect of pioglitazone.
Shadid S; Jensen MD
Diabetes Care; 2002 Feb; 25(2):405. PubMed ID: 11815525
[No Abstract] [Full Text] [Related]
49. [Pioglitazone protects the type-2-diabetes patient from myocardial infarction and stroke].
MMW Fortschr Med; 2007 Aug; 149(31-32):52-3. PubMed ID: 17849787
[No Abstract] [Full Text] [Related]
50. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y; Mahankali A; Matsuda M; Mahankali S; Hardies J; Cusi K; Mandarino LJ; DeFronzo RA
J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
[TBL] [Abstract][Full Text] [Related]
51. Severe but reversible cholestatic liver injury after pioglitazone therapy.
Pinto AG; Cummings OW; Chalasani N
Ann Intern Med; 2002 Nov; 137(10):857. PubMed ID: 12435231
[No Abstract] [Full Text] [Related]
52. New drug overview. Pioglitazone hydrochloride.
Am J Health Syst Pharm; 2000 Jan; 57(2):124-5. PubMed ID: 10688239
[No Abstract] [Full Text] [Related]
53. Pharmacologic therapy for type 2 diabetes mellitus.
DeFronzo RA
Ann Intern Med; 2000 Jul; 133(1):73-4. PubMed ID: 10877745
[No Abstract] [Full Text] [Related]
54. [A case of drug induced liver injury related pioglitazone].
Hisamochi A; Kumashiro R; Koga Y; Tanaka E; Ide T; Hino T; Murashima S; Ogata K; Kuwahara R; Koga H; Shishido S; Ueno T; Sata M; Eguchi T
Nihon Shokakibyo Gakkai Zasshi; 2003 Mar; 100(3):333-6. PubMed ID: 12696176
[No Abstract] [Full Text] [Related]
55. Hepatocellular injury in a patient receiving pioglitazone.
Maeda K
Ann Intern Med; 2001 Aug; 135(4):306. PubMed ID: 11511159
[No Abstract] [Full Text] [Related]
56. Summary for patients. Liver damage in a person taking the diabetes drug pioglitazone.
Ann Intern Med; 2002 Mar; 136(6):I65. PubMed ID: 11900516
[No Abstract] [Full Text] [Related]
57. First experiments in taurine administration for diabetes mellitus. The effect on erythrocyte membranes.
Elizarova EP; Nedosugova LV
Adv Exp Med Biol; 1996; 403():583-8. PubMed ID: 8915397
[No Abstract] [Full Text] [Related]
58. Marked improvement of glycaemic control with pioglitazone in a Type 2 diabetic patient associated with Charcot-Marie-Tooth disease.
Ota T; Osawa K
Diabet Med; 2003 May; 20(5):420-1. PubMed ID: 12752495
[No Abstract] [Full Text] [Related]
59. A new era in type 2 diabetes mellitus treatment?
Laws A
Am J Med; 2001 Jul; 111(1):71-2. PubMed ID: 11448665
[No Abstract] [Full Text] [Related]
60. "Did this drug cause my patient's hepatitis?" and related questions.
Nierenberg DW
Ann Intern Med; 2002 Mar; 136(6):480-3. PubMed ID: 11900502
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
